Sulfamethoxazole + Trimethoprim
Bactrim has antibacterial effects. It contains the active substances: sulfamethoxazole and trimethoprim. The combination of these two substances is known as co-trimoxazole. Before recommending the use of the medicine, the doctor will consider the sensitivity of the microorganisms causing the infection and the possibility of side effects. The therapeutic indications are limited to infections caused by microorganisms sensitive to the medicine. Bactrim should be used to treat or prevent infections, only in cases where it has been confirmed or there is a justified suspicion that they were caused by bacteria or other microorganisms sensitive to the active substances of this medicine. In the absence of such data, in the process of selecting the appropriate antibiotic therapy, local epidemiological conditions and the susceptibility of microorganisms to the medicine should be taken into account. Bactrim is indicated for the treatment of adults and adolescents over 12 years of age.
Indications for use:
Pulmonary infiltrates observed in connection with eosinophilic or allergic pneumonia may manifest as cough and shortness of breath. If these symptoms occur or suddenly worsen, the patient should see a doctor.
Hemophagocytic lymphohistiocytosis
Very rare cases of severe immunological reactions resulting from uncontrolled activation of white blood cells, leading to inflammatory conditions (hemophagocytic lymphohistiocytosis) — which can be life-threatening if not diagnosed and treated early. If multiple symptoms occur simultaneously or with a slight delay, such as fever, lymph node swelling, weakness, dizziness, shortness of breath, cyanosis, or skin rash, the patient should immediately contact their doctor.
Effect on the kidneys
Sulfonamides, including Bactrim, may cause increased urine excretion, especially in patients with heart failure.
The doctor should carefully monitor the potassium level in the blood serum and kidney function in patients:
If the patient has a folic acid deficiency, blood-related side effects may occur. They disappear after the administration of folic acid.
Bactrim should not be used in patients with G6PD enzyme deficiency, except in cases of absolute necessity. In such cases, only minimal doses of the medicine are used.
In patients with renal impairment, the doctor will recommend a dose adjusted for the individual patient based on the results of tests (creatinine clearance), see section 3.
The medicine should be used with caution. The doctor will order more frequent blood tests.
Bactrim is mainly intended for use in children under 12 years of age in the form of a syrup with a strength of (200 mg + 40 mg)/5 ml.
See section 3.
In patients with folic acid deficiency (in elderly people, patients with pre-existing folic acid deficiency, or patients with renal impairment), blood-related side effects occur more frequently. These symptoms disappear after the administration of folic acid. The doctor will order periodic blood tests.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. The doctor will decide on the continuation, possible modification, and method of monitoring the treatment effects. This applies in particular to medicines containing:
In the case of the patient taking the above-mentioned medicines, the doctor will decide whether the patient can take Bactrim at the same time.
It is not recommended to use Bactrim concomitantly with medicines containing:
The frequency and severity of side effects such as bone marrow damage and kidney damage may increase if Bactrim is given concomitantly with other medicines that have a proven effect on reducing the number of bone marrow cells or are harmful to the kidneys), such as nucleoside analogues(used in antitumor and antiviral therapy), tacrolimus(used to prevent transplant rejection), azathioprine(a medicine that inhibits the activity of the immune system), or mercaptopurine(an anticancer and immunosuppressive medicine).
Effect on laboratory test results
The patient should inform their doctor about taking Bactrim if it is necessary to determine the creatinine or methotrexate level in the blood. The doctor will order a laboratory test using an appropriate method.
If the patient is pregnant or breastfeeding, suspects that they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine. The doctor will consider the use of Bactrim in pregnant or breastfeeding women. There is no clear evidence of the risk of fetal malformations in women treated with co-trimoxazole in early pregnancy. However, an increased risk of spontaneous abortion has been observed in women who took trimethoprim or trimethoprim in combination with sulfamethoxazole in the first trimester of pregnancy. Animal studies indicate that very high doses of co-trimoxazole can cause fetal malformations typical of folic acid-lowering substances.
The medicine may be used during pregnancy only if the expected benefits of treatment outweigh the potential risk to the fetus. In such cases, pregnant women or women planning to become pregnant during treatment with Bactrim are recommended to take folic acid at a dose of 5 mg per day. If possible, the use of Bactrim should be avoided in the last period of pregnancy due to the risk of kernicterus in the newborn. Since the active substances of Bactrim pass into breast milk, the doctor will consider the risk to the child (kernicterus, hypersensitivity) in relation to the expected therapeutic benefits for the mother.
There is no available data on the effect on fertility.
There is no data on the effect of the medicine on the ability to drive and use machines.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that the medicine is considered "sodium-free".
This medicine should always be taken according to the doctor's recommendations. In case of doubts, the patient should consult their doctor.
Bactrim is taken orally. It is best to take it after a meal with a sufficient amount of fluids.
Adults and adolescents over 12 years of age with normal kidney function
In the case of acute infections, Bactrim is given for at least 5 days or until the patient has not shown symptoms of infection for at least 2 days. If there is no clinical improvement after a week of treatment, the patient should see their doctor again.
Pneumonia caused by Pneumocystis jirovecii
The treatment uses a dose not exceeding 100 mg/kg body weight per day of sulfamethoxazole and 20 mg/kg body weight per day of trimethoprim in equal divided doses given every 6 hours for 14 days.
Dose - taken every 12 hours | Number of Bactrim tablets | |
Usually used | 2 | |
High, in severe infections | 3 | |
Minimum, in long-term treatment | 1 |
Maximum doses depending on the body weight of patients with pneumonia caused by Pneumocystis jirovecii.
In the prophylaxis of pneumonia caused by Pneumocystis jirovecii, the recommended dose for adolescents and adults is 2 Bactrim tablets once a day. The results of a study conducted in patients with HIV infection also indicate the effectiveness of using 1 Bactrim tablet once a day.
In children, the recommended daily dose for prophylaxis of pneumonia caused by Pneumocystis jiroveciiis 750 mg/m² body surface area per day of sulfamethoxazole with 150 mg/m² body surface area per day of trimethoprim divided into two equal doses, for three consecutive days a week. The total daily dose should not exceed 1600 mg of sulfamethoxazole and 320 mg of trimethoprim.
Treatment with a single dose in uncomplicated, acute urinary tract infections
4 to 6 Bactrim tablets taken once, preferably in the evening after dinner or before bedtime.
Treatment of soft chancre
2 Bactrim tablets twice a day. If there are no signs of improvement after 7 days, the doctor will consider continuing the treatment for another 7 days.
Dosing in patients with renal impairment
Recommended dosing regimen in patients with renal impairment:
Creatinine clearance > 30 ml/min: standard dosing.
Creatinine clearance 15 – 30 ml/min: half of the standard dose.
Creatinine clearance <15 ml min: bactrim should not be used (see section 2).
Dosing in patients undergoing dialysis
Patients undergoing hemodialysis should initially receive a normal loading dose of Bactrim, and then an additional half dose after each hemodialysis. Peritoneal dialysis results in minimal removal of the medicine. It is not recommended to use Bactrim in patients undergoing peritoneal dialysis.
Dosing in elderly patients
In elderly patients with normal kidney function, the same doses as for adults should be used.
In case of any further doubts related to the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Bactrim can cause side effects, although not everybody gets them.
In the recommended doses, Bactrim is generally well tolerated.
Body weight [kg] | Number of Bactrim tablets given every 6 hours |
16 | 1 |
24 | 1 and ½ |
32 | 2 |
40 | 2 and ½ |
48 | 3 |
64 | 4 |
80 | 5 |
Frequent side effects (less than 1 in 10 patients, but more than 1 in 100 patients) are:
Uncommon side effects (not more than 1 in 100 patients) are:
Rare side effects (less than 1 in 1,000 patients, but more than 1 in 10,000 patients) are:
Very rare side effects (less than 1 in 10,000 patients) are:
Side effects with an unknown frequency (cannot be estimated from the available data) are:
Safety in patients with HIV infection
The types of side effects in this patient group are similar to those in the general population of patients taking Bactrim. However, some side effects may occur more frequently and have a different clinical picture. These differences concern the following symptoms:
Very common:
decrease in the number of certain types of blood cells (leukopenia, granulocytopenia, and thrombocytopenia);
increased potassium levels in the blood serum (hyperkalemia);
anorexia, nausea with or without vomiting, diarrhea;
papular rash, pruritus;
fever, usually accompanied by a papular rash;
increased liver enzyme activity (aminotransferases).
Uncommon:
decreased sodium (hyponatremia) or glucose (hypoglycemia) levels in the blood.
If side effects occur, including any not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Al. Jerozolimskie 181C
The medicine should be stored in a place invisible and inaccessible to children.
There are no special recommendations for storage.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste containers. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
White, round, convex tablets on both sides with a dividing line. The packaging contains 20 tablets packed in 2 blisters, in a cardboard box.
To obtain more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
EUMEDICA Pharmaceuticals GmbH
Basler Straße 126
79540 Lörrach, Germany
EUMEDICA Pharmaceuticals GmbH
Basler Straße 126
79540 Lörrach, Germany
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
CEFEA Sp. z o.o. Sp. komandytowa
ul. Działkowa 56
02-234 Warsaw
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warsaw
Synoptis Industrial Sp. z o.o.
ul. Szosa Bydgoska 58
87-100 Toruń
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Marketing authorization number in France, the country of export: 300 106-9
34009 300 106 9 3
Parallel import authorization number: 165/22
Date of leaflet approval: 11.04.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.